Smart ring company Oura seeks digital biomarkers for COVID-19 in research study with University of California, San Francisco

March 24, 2020
Digital Transformation More...
by Danielle Bradnan
Truly disruptive

This research study to identify digital biomarkers comes on the heels of other studies based on smartphones and other wearables for early detection of other medical conditions, such as dementia and depression – as well as, in a notable study with Fitbit, the flu. This research is not only important for developing new tools to get a preliminary diagnosis in advance of testing for COVID-19 but also for advancing research for disease and population health management in the years to come after this crisis has passed. Clients should be looking for research partnerships with wearables startups to identify these biomarkers now as a way to  not only mitigate the current crisis but also continue future plays in healthcare.

For the original news article, click here .

Further Reading

Mumbai-based startup Vivant launches women's health app Nyra for menstrual cycle tracking

News Commentary | June 07, 2019

Based on user‑recorded data, the app is able to provide personalized reproductive health advice. The app is part of a growing trend of investments in women's reproductive health; however, this app is redundant, as the market is saturated with period‑tracking apps of varying quality. While there are ... Not part of subscription

Singaporean digital therapeutics startup Biofourmis raises $35 million for chronic disease management

News Commentary | June 03, 2019

Biofourmis has now brought its total investment raised to over $40 million. It also just obtained FDA 510(k) clearance for RhythmAnalytics, a cloud‑based software that uses deep learning to extract and interpret more than 15 types of cardiac arrhythmias. This investment round was led by big‑name VCs... To read more, click here.

DiaMonTech concludes a €7 million funding round

News Commentary | September 10, 2019

DiaMonTech (Lux Take: Positive) has just secured €7 million in funding just weeks after we interviewed the company. This is a company with a promising noninvasive glucose monitoring technology. Noninvasive glucose monitoring remains the "holy grail" in blood glucose monitoring, and many companies ... Not part of subscription